PlasmaGen Biosciences, a biopharmaceutical company that develops medicines from blood plasma, has raised INR 150 crore in a minority equity funding round led by ViNS Bioproducts.
The round also included investments from high-net-worth individuals, family offices, pharma entrepreneurs and existing investors. Based in Bengaluru, the startup is backed by Eight Roads Ventures and was valued at over ₹1,500 crore in this round.
The fresh funds will be used to expand its international presence, add more products to its portfolio, and strengthen its team and internal systems.
“The past year has been transformational for PlasmaGen, marking a step change in the scale and reach of the company. This momentum has put us on an exponential growth trajectory,” said Vivek V Kamath, chief executive officer of PlasmaGen Biosciences.
“With a clear plan and the support of this financing, we are well positioned to turn our ambition into enduring impact for patients and partners worldwide,” he added.
“From the outset, our objective has been to create a worldclass, India-based plasma biopharmaceutical platform that delivers consistent quality and meaningful patient impact,” said, Vinod Nahar, founder and executive chairman of PlasmaGen Biosciences.
“This investment further strengthens PlasmaGen’s position as a long-term partner to healthcare systems and patients, both in India and internationally,” he added.
Founded in 2010, PlasmaGen Biosciences develops and sells plasma-based medicines such as Immunoglobulin, Albumin, and clotting factors. These medicines help address India’s shortage of critical plasma drugs. The company operates a modern plasma fractionation plant in Kolar, Karnataka, and supplies treatments used in neurology, blood-related disorders and critical care. Its long-term goal is to help India become self-reliant in plasma-based medicines.
PlasmaGen has already identified distribution partners in key global markets and is working on regulatory approvals to begin international sales. While India remains its main market, the company is expanding its presence by reaching more hospitals and doctors through a temperature-controlled (cold-chain) distribution network.
The company started commercial operations in 2024 at its Kolar facility near Bengaluru. PlasmaGen says this is one of only five plasma fractionation plants in India and claims to be the country’s first pure-play plasma biopharma company. Since launching operations, it has reported strong revenue growth and is now preparing to expand globally.
Read More- Q Fund Invests in AI Startup QPioneers in First Funding Round
